Bristol-Myers Squibb Co. cut the sales force for its second best-selling drug, the antipsychotic Abilify, six months after extending its contract to market the product with Tokyo-based Otsuka Pharmaceutical Co. About 25 percent of the positions were eliminated, Brian Henry, a spokesman for New York-based Bristol-Myers, said yesterday in a telephone interview. The move happened this week, he said. He declined to give the number of jobs cut. Bristol-Myers employed about 35,000 people at the end of 2008, according to a regulatory filing. The company doesn’t break out sales divisions.
No comments:
Post a Comment